In this population-based matched cohort of patients with type 2 diabetes, we observed a 14% reduced risk of hospitalization due to HF among new-users of DPP-4 inhibitors, compared to new-users of GLP-1 agonists. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.